Moxduo Must Show Clear Benefit Over Opioid Components, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency hands QRxPharma its third “complete response” letter in less than two years for the fixed-dose combination of immediate-release morphine and oxycodone. New CEO says the company will develop a clinical program to clearly demonstrate Moxduo's benefit.